Skip to main content

Table 1 The laboratory and clinical features of the FMS and control groups

From: Determination of the increased risk of developing atrial fibrillation in fibromyalgia syndrome

 FMS group
n:70
Control group
n:70
p
Age (years)38.0 ± 10.837.8 ± 9.90.516
SBP (mm Hg)123.4 ± 11.9121.6 ± 9.60.739
DBP (mm Hg)79.8 ± 9.578.6 ± 8.90.577
MBP (mmHg)89.43 ± 8.6088.86 ± 9.10.651
Hypertension (n (%))5 (7.1)4 (5.7)0.844
BMI (kg/m2)26.6 ± 5.625.2 ± 4.70.284
Total cholesterol (mg/dL)179.8 ± 20.5178.3 ± 19.80.794
Fasting glucose (mg/dL)87.8 ± 6.788.0 ± 6.60.936
TSH (uIU/mL)1.99 ± 0.381.87 ± 0.460.528
Serum creatinine, mg/dL1.04 ± 0.121.06 ± 0.140.654
Smokers (n (%))11 (15.7)9 (12.8)0.698
  1. SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, BMI body mass index, TSH Thyroid stimulating hormone, FMS Fibromyalgia syndrome